Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ZD 6021

Known as: (3-cyano-N-(2-(3,4-dichlorophenyl)-4-(4-(2-(methylsulfinyl)phenyl)piperidino)butyl)-N-methyl)naphthamide, ZD-6021, ZD6021 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Tachykinin NK receptors (NKRs) differ to a large degree among species with respect to their affinities for small molecule… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2008
2008
Tachykinin NK(2) receptor antagonists are potentially beneficial in treating various disorders including irritable bowel syndrome… Expand
Highly Cited
2007
Highly Cited
2007
We compared the neurokinin 1 receptor (NK1R) antagonists aprepitant, CP-99994 [(2S,3S)-3-(2-methoxybenzylamino)-2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2007
2007
The present study investigates the pharmacology of the cloned neurokinin 1 receptor from the gerbil (gNK(1)R), a species claimed… Expand
2004
2004
This study assessed the involvement of NMDA and group I metabotropic glutamate receptors, and tachykinin NK1 and NK3 receptors… Expand
2002
2002
Through optimization of compounds based on the dual NK(1)/NK(2) antagonist ZD6021, it was found that alteration of two key… Expand
2001
2001
Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues… Expand
2001
2001
The tachykinins, substance P, neurokinin A, and neurokinin B, have been implicated in many diseases. The present study evaluated… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5